PAR 6.52% 24.5¢ paradigm biopharmaceuticals limited..

Did you even read the conclusions of this PHASE 2 study on...

  1. 41 Posts.
    lightbulb Created with Sketch. 18
    Did you even read the conclusions of this PHASE 2 study on Sprifermin that your link referred to:

    "Conclusions and relevance: Among participants with symptomatic radiographic knee osteoarthritis, the intra-articular administration of 100 μg of sprifermin every 6 or 12 months vs placebo resulted in an improvement in total femorotibial joint cartilage thickness after 2 years that was statistically significant, but of uncertain clinical importance; there was no significant difference for 30 μg of sprifermin every 6 or 12 months vs placebo. Durability of response also was uncertain."

    Hardly seem like "competition" based on this study, if you have read any actual detail on the Paradigm PHASE 2 results.


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.